Guided Therapeutics Submits PMA Amendment to FDA for LuViva® Advanced Cervical Scan

  Guided Therapeutics Submits PMA Amendment to FDA for LuViva® Advanced
  Cervical Scan

Business Wire

NORCROSS, Ga. -- November 13, 2012

Guided Therapeutics, Inc., (OTCBB: GTHP) (OTCQB: GTHP), today announced that
it has submitted its premarket approval (PMA) Amendment for the LuViva^®
Advanced Cervical Scan, a non-invasive device used to detect cervical disease
that leads to cancer, instantly and at the point of care.

The amendment is in response to a “not approvable” letter received by the
company in January and includes additional data analysis requested by the U.S.
Food and Drug Administration (FDA).

"We are pleased to move the FDA review process forward with the filing of the
amended PMA for LuViva,” said Mark L. Faupel, Ph.D., President and CEO of
Guided Therapeutics. “We have worked with the agency over the last several
months to provide responses to the key questions in the PMA amendment and are
hopeful this filing will ultimately lead to approval for the product. We
believe that once approved, LuViva will have a very positive impact on the
U.S. healthcare system by improving the standard of care for the early
detection of cervical disease, providing women and doctors with the first test
with instant results and detecting cervical disease at an earlier stage, when
it can be better treated.”

LuViva has been under FDA PMA review since September 23, 2010. The company
received a “not approvable” letter for the product on January 20, 2012. In
July, 2012 the company met with the agency and agreed to file a PMA amendment
to address the agency’s questions stemming from the “not approvable” letter.
With the PMA amendment now formally submitted, the FDA has 180 days during
which it can respond.

LuViva currently has marketing approval from Health Canada and received its
first CE Mark, an ISO 60601 Edition 2 Notification, in July. The company is in
the process of testing the LuViva system for compliance with the Edition 3 CE
Mark requirements, which the company expects to achieve near the end of this
year. Guided Therapeutics was awarded ISO 13485 certification in January,

About LuViva^® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the cervix
with light and uses spectroscopy to measure how light interacts with the
cervical tissue. Spectroscopy identifies chemical and structural indicators of
precancer that may be below the surface of the cervix or misdiagnosed as
benign. This technique is called biophotonics. Unlike Pap, HPV tests or
biopsies, LuViva does not require laboratory analysis or a tissue sample, and
is designed to provide results immediately, which eliminates costly, painful
and unnecessary testing. LuViva is designed for use with women who have
undergone initial screening and are called back for follow up with a
colposcopy examination, which in many cases, involves taking a biopsy of the
cervix. The device is used in conjunction with the LuViva^® Cervical Guide
single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is developing a rapid
and painless testing platform for the early detection of disease based on its
patented biophotonic technology that utilizes light to detect disease at the
cellular level. The Company’s first planned product is the LuViva^® Advanced
Cervical Scan, a non-invasive device used to detect cervical disease instantly
and at the point of care. In a multi-center clinical trial, with women at risk
for cervical disease, the technology was able to detect cervical cancer up to
two years earlier than conventional modalities, according to published
reports. Guided Therapeutics has also entered into a partnership with Konica
Minolta to develop a non-invasive test for the early detection of esophageal
cancer using the technology platform. For more information, visit:

The Guided Therapeutics LuViva^® Advanced Cervical Scan is an investigational
device and is limited by federal law to investigational use. LuViva, the wave
logo and "Early detection, better outcomes" are registered trademarks owned by
Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject
areas discussed in this news release that are not historical or current facts
deal with potential future circumstances and developments. The discussion of
such matters and subject areas is qualified by the inherent risks and
uncertainties surrounding future expectations generally and also may
materially differ from Guided Therapeutics’ actual future experience involving
any of or more of such matters and subject areas. Such risks and uncertainties
include those related to the early stage of products in development, the
uncertainty of market acceptance of products, the uncertainty of development
or effectiveness of distribution channels, the intense competition in the
medical device industry, the uncertainty of capital to develop products, the
uncertainty of regulatory approval of products, dependence on licensed
intellectual property, as well as those that are more fully described from
time to time under the heading “Risk Factors” in Guided Therapeutics’ reports
filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K
for the fiscal year ended December 31, 2011, and subsequent quarterly reports.


Cameron Associates
Alison Ziegler, 212-554-5469
Guided Therapeutics
Bill Wells, 770-242-8723 Ext. 241
Press spacebar to pause and continue. Press esc to stop.